However, in the I-SPY2 study, wherein pre-operative chemotherapy was administered with or without pembrolizumab in a curative-intent population, the estimated pCR rate was 34 versus 13%, respectively, in women with hormone receptor-positive/HER2-normal breast cancer [15]. Here, ERBB2 is linked to breast cancer.